Treatment of type 2 diabetes in children: what are the specific considerations?
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Treatment of type 2 diabetes in children : what are the specific considerations? / Grondahl, Magnus F. G.; Johannesen, Jesper; Kristensen, Kurt; Knop, Filip K.
In: Expert Opinion on Pharmacotherapy, Vol. 22, No. 16, 2021, p. 2127-2141.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Treatment of type 2 diabetes in children
T2 - what are the specific considerations?
AU - Grondahl, Magnus F. G.
AU - Johannesen, Jesper
AU - Kristensen, Kurt
AU - Knop, Filip K.
PY - 2021
Y1 - 2021
N2 - Introduction: The number of individuals under 18 years of age with type 2 diabetes is increasing at an alarming rate worldwide. These patients are often characterized by obesity and they often experience a more rapid disease progression than adults with type 2 diabetes. Thus, focus on prevention and management of complications and comorbidities is imperative. With emphasis on weight loss and optimal glycemic control, treatment includes lifestyle changes and pharmacotherapy, which in this patient group is limited to metformin, liraglutide and insulin. In selected cases, bariatric surgery is indicated. Areas covered: This perspective article provides an overview of the literature covering pathophysiology, diagnosis, characteristics and treatment of pediatric type 2 diabetes, and outlines the gaps in our knowledge where further research is needed. The paper draws on both mechanistic studies, large scale intervention trials, epidemiological studies and international consensus statements. Expert opinion: Type 2 diabetes in pediatric patients is an increasing health care problem, and the current treatment strategies do not successfully meet the many challenges and obstacles in this patient group. Treatments must be early, intensive, multifaceted and durable. Also, prevention of obesity and type 2 diabetes in at-risk children should be addressed and prioritized on all levels.
AB - Introduction: The number of individuals under 18 years of age with type 2 diabetes is increasing at an alarming rate worldwide. These patients are often characterized by obesity and they often experience a more rapid disease progression than adults with type 2 diabetes. Thus, focus on prevention and management of complications and comorbidities is imperative. With emphasis on weight loss and optimal glycemic control, treatment includes lifestyle changes and pharmacotherapy, which in this patient group is limited to metformin, liraglutide and insulin. In selected cases, bariatric surgery is indicated. Areas covered: This perspective article provides an overview of the literature covering pathophysiology, diagnosis, characteristics and treatment of pediatric type 2 diabetes, and outlines the gaps in our knowledge where further research is needed. The paper draws on both mechanistic studies, large scale intervention trials, epidemiological studies and international consensus statements. Expert opinion: Type 2 diabetes in pediatric patients is an increasing health care problem, and the current treatment strategies do not successfully meet the many challenges and obstacles in this patient group. Treatments must be early, intensive, multifaceted and durable. Also, prevention of obesity and type 2 diabetes in at-risk children should be addressed and prioritized on all levels.
KW - Adolescents
KW - children
KW - insulin
KW - liraglutide
KW - metformin
KW - obesity
KW - pediatric
KW - type 2 diabetes
KW - GLUCAGON-LIKE PEPTIDE-1
KW - GASTRIC BYPASS-SURGERY
KW - BETA-CELL FUNCTION
KW - CARDIOVASCULAR RISK-FACTORS
KW - BARIATRIC SURGERY
KW - WEIGHT-LOSS
KW - CLINICAL-TRIAL
KW - LIRAGLUTIDE PHARMACOKINETICS
KW - INSULIN-RESISTANCE
KW - PEDIATRIC-PATIENTS
U2 - 10.1080/14656566.2021.1954160
DO - 10.1080/14656566.2021.1954160
M3 - Journal article
C2 - 34420454
VL - 22
SP - 2127
EP - 2141
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
SN - 1465-6566
IS - 16
ER -
ID: 278038102